IMUNON to Participate in Upcoming Investor Conferences
LAWRENCEVILLE, N.J., Oct. 08, 2026 (GLOBE NEWSWIRE) -- IMUNON, Inc. (Nasdaq: IMNN), a clinical-stage biotechnology company developing DNA-mediated immunotherapies, today announced that Stacy Lindborg, Ph.D., President and Chief Executive Officer, will participate in the following October 2026 investor conferences.
Covered in this story
What has happened since
- Ginkgo Bioworks Holdings Inc Class is down 10.8% since this was published, 12 days ago.
Price move measured from the close nearest publication to the latest quote.
Call it yourself
No calls on $DNA yet. A scorecard is a price target with a date and the working behind it — tracked, settled and scored in public.
Make the first call on Ginkgo Bioworks Holdings Inc Class →Summary aggregated from GlobeNewswire's public RSS feed. The full reporting belongs to GlobeNewswire — please read it on their site.